Order Article Reprints

Orlandi A, Iattoni E, Pizzuti L, Fabbri A, Botticelli A, Di Dio C, Palazzo A, Garufi G, Indellicati G, Alesini D, et al. Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series. Journal of Personalized Medicine. 2020; 10(4):291. https://doi.org/10.3390/jpm10040291

Orlandi, Armando, Elena Iattoni, Laura Pizzuti, Agnese Fabbri, Andrea Botticelli, Carmela Di Dio, Antonella Palazzo, Giovanna Garufi, Giulia Indellicati, Daniele Alesini, and et al. 2020. "Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series" Journal of Personalized Medicine 10, no. 4: 291. https://doi.org/10.3390/jpm10040291

Orlandi, A., Iattoni, E., Pizzuti, L., Fabbri, A., Botticelli, A., Di Dio, C., Palazzo, A., Garufi, G., Indellicati, G., Alesini, D., Carbognin, L., Paris, I., Vaccaro, A., Moscetti, L., Fabi, A., Magri, V., Naso, G., Cassano, A., Vici, P., ... Tortora, G. (2020). Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series. Journal of Personalized Medicine, 10(4), 291. https://doi.org/10.3390/jpm10040291